Journal article
Volumetric and spatial accuracy of computed tomography perfusion estimated ischemic core volume in patients with acute ischemic stroke
JW Hoving, HA Marquering, CBLM Majoie, N Yassi, G Sharma, DS Liebeskind, A Van Der Lugt, YB Roos, W Van Zwam, RJ Van Oostenbrugge, M Goyal, JL Saver, TG Jovin, GW Albers, A Davalos, MD Hill, AM Demchuk, S Bracard, F Guillemin, KW Muir Show all
Stroke | Published : 2018
Abstract
Background and Purpose: The volume of estimated ischemic core using computed tomography perfusion (CTP) imaging can identify ischemic stroke patients who are likely to benefit from reperfusion, particularly beyond standard time windows. We assessed the accuracy of pretreatment CTP estimated ischemic core in patients with successful endovascular reperfusion. Methods: Patients from the HERMES (Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials) and EXTEND-IA TNK (Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke) databases who had pretreatment CTP, >50% angiographic reperfusion, and follow-up magnetic resonance imaging at 24 hours were inc..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
Dr Majoie has consulted for Stryker and the Dutch Heart Foundation (paid to institution). Dr Marquering is a founder and shareholder of Nico-lab. Dr van der Lugt has consulted for Stryker and reports grants to his institution from Penumbra. Dr van Zwam has consulted for Stryker and Cerenovus (paid to institution). Dr Saver is an employee of the University of California (UC) that has patent rights on retrieval devices for stroke; has served as an unpaid site investigator in multicenter trials sponsored by Medtronic, Stryker, and Neuravi for which the UC Regents received payments on the basis of clinical trial contracts for the number of subjects enrolled; has consulted for Medtronic, Stryker, and Neuravi; and has received stock options from Rapid Medical for services as a consultant. Dr Jovin has consulted for Stryker Neurovascular as Principal Investigator for the DAWN trial; has consulted for Fundacio Ictus as member of the Executive Committee RACECAT trial (Direct Transfer to an Endovascular Center Compared to Transfer to the Closest Stroke Center in Acute Stroke Patients With Suspected Large Vessel Occlusion); has served as advisor for Silk Road, Anaconda, Route92, FreeOX Biotech, and Blockade Medical; and has served in the Data Safety Monitoring Board of Cerenovus. Dr White has consulted for Microvention and Stryker and his institution received a grant from Microvention. Dr Muir reports grants to his institution for the PISTE trial (Pragmatic Ischaemic Stroke Thrombectomy Evaluation) from the Stroke Association, the NIHR (National Institute for Health Research) Health Technology Assessment programme, Medtronic, and Codman. Dr Goyal has a licensing agreement with GE Healthcare for further development of systems of efficient stroke diagnosis. Dr Albers reports research support from the National Institutes of Health (U01NS092076, 1U10NS086487), equity interest in iSchemaView, and consulting fees from Medtronic and iSchemaView. Dr Davalos has consulted for Medtronic; reports a research grant by Medtronic; and reports engagements as lecturer for Medtronic. Dr Hill reports a research grant from Medtronic and reports stock ownership in Calgary Scientific Inc. Dr Demchuk reports honoraria for CME events from Medtronic. P. J. Mitchell reports unrestricted grants to his institution from Medtronic, Stryker, and Codman Johnson and Johnson, and has consulted for Codman Johnson and Johnson, and Microvention. Dr Donnan reports speaking engagements with Boehringer Ingelheim. Dr Davis and Dr Campbell report research grants from NHMRC (National Health and Medical Research Council) Australia. The other authors report no conflicts.